A Prospective,Observational Follow-up Study of Nucleoside Treated Patients With Chronic Hepatitis B (OCEAN Study)
NCT ID: NCT03358108
Last Updated: 2018-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1600 participants
OBSERVATIONAL
2018-02-27
2022-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
NCT06368882
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
NCT06357806
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
NCT02838810
Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy
NCT03181113
A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue
NCT01855997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: interferon group
formerly interferon group (including interferon alone or interferon combined with other drugs)
No interventions assigned to this group
Group B:nucleoside analogue group
formerly nucleoside analogue treatment group. Each group was followed for five years
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have finished the OSST,COST,Endeavor, Anchor,NPGV studies;
3. Agree to participate in the study and sign the patient informed consent.
Exclusion Criteria
2. unable or unwilling to provide informed consent or follow the research requirements
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qin Ning
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qin Ning
Director and Chair of Department of Infectious Diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ning Qin, Doctor
Role: PRINCIPAL_INVESTIGATOR
Department of Infectious Diseases, Tongji Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BeiJing YouAn Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
Zhejiang, Hangzhou, China
Tongji Hospital
Wuhan, Hubei, China
Departmen of infectious disease, Xiangya Hospital, Central-south Universit
Changsha, Hunan, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
The Second Hospital of Nanjing
Nanjing, Jiangsu, China
Traditional Chinese Medicine,Xiamen Hospital
Shantou, Xiamen, China
The first affiliated hospital of Wenzhou medical universtiy
Wenzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chen Xinyue, Doctor
Role: primary
Jiang Jiaji, Doctor
Role: primary
Qi Xia
Role: primary
Tan Deming, Doctor
Role: primary
Chen Yongping, Doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OCEAN study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.